BioCryst Pharma (BCRX) PT Lowered to $13 at Oppenheimer
Tweet Send to a Friend
Oppenheimer analyst Justin Kim lowered the price target on BioCryst Pharma (NASDAQ: BCRX) to $13.00 (from $16.00) while maintaining an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
